Co-Authors
This is a "connection" page, showing publications co-authored by KEVIN GAREY and PABLO C OKHUYSEN.
Connection Strength
0.927
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 Jun 14; 78(6):1462-1472.
Score: 0.242
-
Increased Prevalence of Clostridioides difficile Infection Among Pediatric Oncology Patients: Risk Factors for Infection and Complications. Pediatr Infect Dis J. 2024 Feb 01; 43(2):136-141.
Score: 0.235
-
Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer. Infect Dis Ther. 2023 Jan; 12(1):209-225.
Score: 0.218
-
Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis. 2021 05 18; 72(10):e460-e465.
Score: 0.196
-
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):964-8.
Score: 0.019
-
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol. 2006 May; 101(5):1112-6.
Score: 0.017